Search Results

Ospemifene 100 mg  | 99.73%

TargetMol

Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.

More Information Supplier Page

Ospemifene 200 mg  | 99.73%

TargetMol

Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.

More Information Supplier Page

RBC8 100 mg  | 99.81%

TargetMol

RBC8 is a specific GTPases RalA/RalB inhibitor by inhibiting the binding of Ral to its effector RALBP1, no inhibition on the GTPases RhoA and Ras.

More Information Supplier Page

SB-705498 50 mg  | 98.00%

TargetMol

SB705498 is a TRPV1 antagonist for hTRPV1. SB-705498 has been investigated for the treatment of Rhinitis, Chronic Cough, and Non-allergic Rhinitis.

More Information Supplier Page

SB-705498 25 mg  | 98.00%

TargetMol

SB705498 is a TRPV1 antagonist for hTRPV1. SB-705498 has been investigated for the treatment of Rhinitis, Chronic Cough, and Non-allergic Rhinitis.

More Information Supplier Page

SB-705498 10 mg  | 98.00%

TargetMol

SB705498 is a TRPV1 antagonist for hTRPV1. SB-705498 has been investigated for the treatment of Rhinitis, Chronic Cough, and Non-allergic Rhinitis.

More Information Supplier Page

Retapamulin 10 mg  | 99.82%

TargetMol

Retapamulin, a Pleuromutilin Antibacterial, binds to both E. coli and S. aureus ribosomes with similar potencies (Kd: 3 nM).

More Information Supplier Page